(Stroke. 2000;31:2569.)
© 2000 American Heart Association, Inc.
Original Contribution |
Resource Utilization and Costs of Stroke Unit Care Integrated in a Care Continuum: A 1-Year Controlled, Prospective, Randomized Study in Elderly Patients
The Göteborg 70+ Stroke Study
From the Institute of Clinical Neuroscience, Neurological Disease Section (L.C., G.G.-H., C.B.), and the Department of Medicine (B.F.), Sahlgrenska University Hospital, and the Department of Occupational Therapy and Physiotherapy, College of Health and Caring Science (L.C., G.G.-H.), Göteborg University, Göteborg, Sweden, and the Centre for Health Economics, Stockholm School of Economics (M.J.), Stockholm, Sweden.
Correspondence to Prof Christian Blomstrand, Institute of Clinical Neuroscience, Neurological Disease Section, Sahlgrenska University Hospital, SE 413 45 Göteborg, Sweden. E-mail cbl{at}neuro.gu.se
Background and Purpose—The aim of the present study was to examine resource utilization during a 12-month period after acute stroke in elderly patients randomized to care in an acute stroke unit integrated with a care continuum compared with conventional care in general medical wards. A secondary aim was to describe costs related to the severity of stroke.
Methods—Two hundred forty-nine consecutive patients aged 
70
years with acute stroke within 7 days before admission, living in their
own homes in Göteborg, Sweden, without recognized need of care
were randomized to 2 groups: 166 patients were assigned to nonintensive
stroke unit care with a care continuum, and 83 patients were assigned
to conventional care. There was no difference in mortality or the
proportion of patients living at home after 1 year. Main outcomes were
costs from inpatient care, outpatient care, and informal care.
Results—Mean annual cost per patient was 170 000 Swedish crowns (SEK) (equivalent to $25 373) and 191 000 SEK ($28 507) in the stroke unit and the general medical ward groups, respectively (P=NS). Seventy percent of the total cost was for inpatient care, and 30% was for outpatient and informal care. For patients with mild, moderate, and severe stroke, the mean annual costs per patient were 107 000 SEK ($15 970), 263 000 SEK ($39 254), and 220 000 SEK ($32 836), respectively (P<0.001). There was no statistical difference in age or nonstroke diagnosis.
Conclusions—The total costs the first year did not differ significantly between the treatment groups in this prospective study. The total annual cost per patient showed a very large variation, which was related to stroke severity at onset and not to age or nonstroke diagnoses. Costs other than those for hospital care constituted a substantial fraction of total costs and must be taken into account when organizing the management of stroke patients. The high variability in costs necessitates a larger study to assess long-term cost effectiveness.
Key Words: costs and cost analysis • elderly • stroke units • Sweden
This article has been cited by other articles:
 |
|
 |
|
  A. I. Qureshi, M. F. K. Suri, A. Nasar, J. F. Kirmani, M. A. Ezzeddine, A. A. Divani, and W. H. Giles Changes in Cost and Outcome Among US Patients With Stroke Hospitalized in 1990 to 1991 and Those Hospitalized in 2000 to 2001 Stroke, July 1, 2007; 38(7): 2180 - 2184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Johansson, P. E. Tillgren, K. A. Guldbrandsson, and L. A. Lindholm A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit-and-Win contest for mothers of small children Scand J Public Health, October 1, 2005; 33(5): 343 - 352. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Weinrich, M. Stuart, and T. Hoyer Rules for Rehabilitation: An Agenda for Research Neurorehabil Neural Repair, June 1, 2005; 19(2): 72 - 83. [Abstract] [PDF]
|
|
|
|
 |
|
 P. S.J. Miller, M. F. Drummond, L. K. Langkilde, J. J.V. McMurray, and M. Ogren Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation Eur. Heart J. Suppl., May 1, 2005; 7(suppl_C): C41 - C54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S.J. Miller, F. L. Andersson, and L. Kalra Are Cost Benefits of Anticoagulation for Stroke Prevention in Atrial Fibrillation Underestimated? Stroke, February 1, 2005; 36(2): 360 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Rundek, K. Nielsen, S. Phillips, K. C. Johnston, M. Hux, D. Watson, and for the GAIN Americas Investigators Health Care Resource Use After Acute Stroke in the Glycine Antagonist in Neuroprotection (GAIN) Americas Trial Stroke, June 1, 2004; 35(6): 1368 - 1374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Patel, M. Knapp, A. Evans, I. Perez, and L. Kalra Training care givers of stroke patients: economic evaluation BMJ, May 8, 2004; 328(7448): 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Patel, M. Knapp, I. Perez, A. Evans, and L. Kalra Alternative Strategies for Stroke Care: Cost-Effectiveness and Cost-Utility Analyses From a Prospective Randomized Controlled Trial Stroke, January 1, 2004; 35(1): 196 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yoneda, T. Uehara, H. Yamasaki, Y. Kita, M. Tabuchi, and E. Mori Hospital-Based Study of the Care and Cost of Acute Ischemic Stroke in Japan Stroke, March 1, 2003; 34(3): 718 - 724. [Abstract] [Full Text] [PDF]
|
|